@article{maud2012antiangiogenic,
  title = {Anti-Angiogenic Therapy Combined with Chemoradiotherapy for Patients with Localized Advanced Rectal Cancer},
  author = {Verstraete Maud and Debucquoy Annelies and Sagaert Xavier and Van Cutsem Eric and Haustermans Karin},
  year = 2012,
  url = {https://ibimapublishing.com/articles/ACRT/2012/796042/},
  journal = {Advances in Cancer Research & Treatment},
  volume = 2012 (2012),
  pages = 31,
  doi = 10.5171/2012.796042,
  abstract = {In the last decade, major advances have been achieved in the treatment of rectal cancer. Results of randomized controlled trials have led to the introduction of total mesorectal excision and preoperative (chemo) radiotherapy as a standard multimodal treatment approach. By combining these different treatment modalities, patients are less likely to suffer local recurrence and are more likely to maintain sphincter function and retain a reasonably good quality of life. To further improve the treatment response, many efforts have been made to integrate targeted biological agents into the conventional therapy. Anti-angiogenic treatment has been shown in preclinical and clinical studies to possibly potentiate chemoradiosensitivity. The researchers present an overview of the mechanisms of action and a summary of published results of chemoradiotherapy with anti-angiogenic drugs in the treatment of locally advanced rectal carcinoma. At present, many obstacles still have to be conquered to use this combination in daily clinical routine. Problems of resistance, invasion and metastasis as well as timing and dosing of the combination therapy when using anti-angiogenic compounds are discussed in this review.  Also, attention for better response prediction and better understanding of the complexity of anti-angiogenic therapy in combination with chemoradiation is needed to lead to future improvements in the use of these agents in the clinic.},
  keywords = {Rectal cancer — anti-angiogenic therapy — radiotherapy.},
  note = Article ID: 796042
}